Application of Biomarkers in Neurologic… | Clinical Trial

Key information

Conditions

Biomarkers

Sex eligibility

All sexes

Study type

Observational

Primary location

First Hospital of Jilin University

Changchun, Jilin, 130000, China

Location status: Recruiting

Location contact

Yi Yang, MD, PhD

CONTACT

[email protected]

About this study

With the rise and continuous development of omics technology and bioinformatics technology, some scholars have applied proteomics technology and metabolomics technology to study the brain tissue, plasma and CSF of patients with nervous system diseases, so as to screen out potential biomarkers, with a view to providing new research ideas for pathogenesis and early diagnosis of neurological diseases. At present, the research on some novel biomarkers is still in its infancy, and many key problems remain to be solved. It is necessary to further determine the expression level of biomarkers in normal human body and the characteristics of biomarkers in patients with neurological diseases.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with neurological diseases;
Subjects or legal agents agree to participate in the study and sign the informed consent.

Exclusion criteria

Participating in other clinical investigators;
Unwilling to be followed up or poor treatment compliance;
Other conditions considered unsuitable for inclusion by the researchers.

Treatment and study plan

Primary outcomes

mRS score in 90 days

Time frame: 3 months

The proportion of 3-month good functional outcome (mRS Score 0-2) in patients with neurological diseases was evaluated by mRS Score

Study contacts

Contact information is provided by the study sponsor or research team.

Yi YY Yang, Ph.D.

CONTACT

[email protected]

18186872986 ext. 86

Zhen-Ni GZ GUO, M.D.

CONTACT

[email protected]

18186872986 ext. 86

Sponsors and collaborators

Lead sponsor

Yi Yang

Other

Registry information

Important dates

Study start: 2023
Primary completion: 2030
Study completion: 2031
First posted: May 31, 2023
Registry last updated: Mar 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting